C. Westland

1.5k total citations
24 papers, 1.1k citations indexed

About

C. Westland is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, C. Westland has authored 24 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 16 papers in Hepatology and 8 papers in Infectious Diseases. Recurrent topics in C. Westland's work include Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (15 papers) and HIV/AIDS drug development and treatment (7 papers). C. Westland is often cited by papers focused on Hepatitis C virus research (16 papers), Hepatitis B Virus Studies (15 papers) and HIV/AIDS drug development and treatment (7 papers). C. Westland collaborates with scholars based in United States, France and Greece. C. Westland's co-authors include Barry Boehm, Bradford Clark, Ellis Horowitz, Raymond Madachy, Richard W. Selby, Carol Brosgart, Stephanos J. Hadziyannis, Craig S. Gibbs, William E. Delaney and John Fry and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and Hepatology.

In The Last Decade

C. Westland

24 papers receiving 1.0k citations

Peers

C. Westland
Michele Bevilacqua Italy
Wu Zhou China
W. Lam United Kingdom
Sunil Kumar Gupta India
Shigeru Chiba Japan
Mark Marron United States
Benjamin J. Keller United States
Shinsuke Nakajima Japan
Matthew Might United States
Bin Liang China
Michele Bevilacqua Italy
C. Westland
Citations per year, relative to C. Westland C. Westland (= 1×) peers Michele Bevilacqua

Countries citing papers authored by C. Westland

Since Specialization
Citations

This map shows the geographic impact of C. Westland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Westland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Westland more than expected).

Fields of papers citing papers by C. Westland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Westland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Westland. The network helps show where C. Westland may publish in the future.

Co-authorship network of co-authors of C. Westland

This figure shows the co-authorship network connecting the top 25 collaborators of C. Westland. A scholar is included among the top collaborators of C. Westland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Westland. C. Westland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gane, Ed, Christian Schwabe, Elina Berliba, et al.. (2021). Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. Journal of Antimicrobial Chemotherapy. 77(4). 1102–1110. 11 indexed citations
2.
Gane, Edward, Catherine Stedman, Matthew W. McClure, et al.. (2017). Short duration treatment with AL-335 and odalasvir, with or without simeprevir, in treatment naïve patients with hepatitis C infection with or without cirrhosis. Journal of Hepatology. 66(1). S82–S82. 4 indexed citations
3.
Berliba, Elina, Tengiz Tsertsvadze, D. Guyader, et al.. (2016). AL-335, a Once-Daily Pangenotypic Nucleotide HCV Polymerase Inhibitor, Demonstrates Potent Antiviral Activity over 7 Days in Treatment-Naïve Genotype 1-4 Patients. Journal of Hepatology. 64(2). S404–S405. 3 indexed citations
4.
Marcellin, Patrick, Simona Georgiana Popa, Adrian Streinu‐Cercel, et al.. (2013). 866 ALS-2200, A NOVEL ONCE-DAILY NUCLEOTIDE HCV POLYMERASE INHIBITOR, DEMONSTRATED POTENT ANTIVIRAL ACTIVITY IN TREATMENT-NAÏVE PATIENTS WITH COMPENSATED CIRRHOSIS OR GENOTYPE 2–4 CHRONIC HEPATITIS C. Journal of Hepatology. 58. S355–S355. 3 indexed citations
5.
Lonial, Sagar, Ravi Vij, Thierry Façon, et al.. (2011). Phase I trial of elotuzumab, lenalidomide, and low-dose dexamethasone in patients with relapsed or refractory multiple myeloma.. Journal of Clinical Oncology. 29(15_suppl). 8076–8076. 6 indexed citations
6.
Lonial, Sagar, Ravi Vij, Jean‐Luc Harousseau, et al.. (2010). Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.. Journal of Clinical Oncology. 28(15_suppl). 8020–8020. 6 indexed citations
7.
Westland, C., Hao Yang, William E. Delaney, et al.. (2005). Activity of adefovir dipivoxil against all patterns of lamivudine‐resistant hepatitis B viruses in patients. Journal of Viral Hepatitis. 12(1). 67–73. 54 indexed citations
8.
Izzedine, Hassane, Jean‐Sébastien Hulot, Vincent Launay‐Vacher, et al.. (2004). Renal safety of adefovir dipivoxil in patients with chronic hepatitis B: Two double-blind, randomized, placebo-controlled studies. Kidney International. 66(3). 1153–1158. 127 indexed citations
9.
Shiffman, M., Patrick Marcellin, L. Jeffers, et al.. (2004). 45 HBsAg seroconversion in adefovir dipivoxil (ADV) treated chronic hepatitis B (CHB) patients. Journal of Hepatology. 40. 17–17. 12 indexed citations
10.
11.
Xiong, S., C. Westland, William E. Delaney, et al.. (2003). Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV). Journal of Hepatology. 38. 182–182. 35 indexed citations
12.
Neumann, Avidan U., Manuel Tsiang, Michael Wulfsohn, et al.. (2003). Predicting HBEAG loss by HBV DNA early kinetics and HBV genotype during treatment of HBEAG+ chronic hepatitis B (CHB) patients with adefovir dipivoxil (ADV). Journal of Hepatology. 38. 26–26. 3 indexed citations
13.
Yang, Hong, et al.. (2003). In vitro antiviral susceptibility of full-length clinical hepatitis B virus isolates cloned with a novel expression vector. Antiviral Research. 61(1). 27–36. 72 indexed citations
14.
Westland, C., N.A. Terrault, Fabien Zoulim, et al.. (2003). 10 Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipivoxil treatment. Hepatology. 38. 160–160. 2 indexed citations
15.
16.
Westland, C., William E. Delaney, Vincent Thibault, et al.. (2003). Resistance profile of adefovir dipivoxil (ADV) in immunocompetent and immunocompromised chronic hepatitis B patients after 48 weeks of adefovir dipivoxil therapy. Journal of Hepatology. 38. 182–182. 6 indexed citations
17.
Heathcote, E. Jenny, Quang Minh Thai, Manuel Tsiang, et al.. (2001). Dynamics analyses provide insight into the influence of precore mutations on the mechanisms of viral CL. Journal of Hepatology. 34. 167–168. 2 indexed citations
18.
Gibbs, Craig S., et al.. (1998). HBV polymerase mutations associated with resistance to lamivudine and famciclovir do not decrease sensitivity to adefovir. Journal of Hepatology. 28. 111–111. 3 indexed citations
19.
Masliah, Eliezer, C. Westland, Edward Rockenstein, et al.. (1997). Amyloid precursor proteins protect neurons of transgenic mice against acute and chronic excitotoxic injuries in vivo. Neuroscience. 78(1). 135–146. 101 indexed citations
20.
Westland, C.. (1996). A Rational Choice Model of Computer and Network Crime. International Journal of Electronic Commerce. 1(2). 109–126. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michele Bevilacqua Breakdown of academic impact, for papers by Wu Zhou Breakdown of academic impact, for papers by W. Lam Breakdown of academic impact, for papers by Sunil Kumar Gupta Breakdown of academic impact, for papers by Shigeru Chiba Breakdown of academic impact, for papers by Mark Marron Breakdown of academic impact, for papers by Benjamin J. Keller Breakdown of academic impact, for papers by Shinsuke Nakajima Breakdown of academic impact, for papers by Matthew Might Breakdown of academic impact, for papers by Bin Liang
Rankless by CCL
2026